{
    "clinical_study": {
        "@rank": "46894", 
        "arm_group": [
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Plasmapheresis (PP) x 3, at 40-60 cc/kg.\nImmunoglobulin (IVIg), to be administered after each PP"
            }, 
            {
                "arm_group_label": "Soliris (eculizumab)", 
                "arm_group_type": "Experimental", 
                "description": "1200 mg first dose (Time: Screening/Week \"0\", after Biopsy Proven AMR)\n900 mg weekly for 4 doses (Weeks 1, 2, 3, 4)\n1200 mg week 5\nWeek 6: If donor specific antibody < 50% of baseline DSA then no further treatment, otherwise 1200 mg weeks 7, 9"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and\n      Immunoglobulin (IVIg) for the treatment of AMR in renal transplant recipients.  All patients\n      will be evaluated from the time of AMR diagnosis for 12 months."
        }, 
        "brief_title": "Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation", 
        "condition": [
            "Antibody-mediated Rejection", 
            "Humoral Rejection"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult renal transplant recipients, men and women between 18 and 75 years of age.\n\n          2. Any patient with acute graft dysfunction (elevation of creatinine above post\n             transplant nadir)\n\n             AND, two out of three, of the following Inclusion Criteria:\n\n          3. Presence of circulating anti HLA antibody (DSA).\n\n          4. Histological findings compatible with Banff Class II or III AMR on transplant biopsy.\n\n          5. Peritubular capillary c4d positivity on transplant biopsy.\n\n        Exclusion Criteria:\n\n          1. Patients that have received eculizumab prior to enrolling in the study.\n\n          2. Patients with ongoing non-acute antibody mediated rejection.\n\n          3. Patients with predominantly chronic antibody mediated rejection or interstitial\n             fibrosis/tubular atrophy.\n\n          4. History of severe cardiac disease (e.g., New York Heart Association [NYHA] Functional\n             Class III or IV, myocardial infarction \u2264 6 months of randomization, ventricular\n             tachyarrhythmias requiring ongoing treatment, unstable angina or other significant\n             cardiovascular diseases)\n\n          5. Prior splenectomy\n\n          6. Has a known bleeding disorder\n\n          7. Has any active bacterial or other infection which is clinically significant in the\n             opinion of the Investigator and is a contraindication to transplantation\n\n          8. Has participated in any other investigational drug study or was exposed to an\n             investigational drug or device within 30 days of screening\n\n          9. Has received rituximab (Rituxan\u00ae) \u2264 3 months prior to screening\n\n         10. Has received bortezomib (Velcade\u00ae) \u2264 3 months prior to screening\n\n         11. Has received alemtuzumab (Campath\u00ae) \u2264 6 months prior to screening\n\n         12. Need for concurrent treatment with anti thymocyte globulin (Thymoglobulin\u00ae)\n\n         13. Hypersensitivity to murine proteins or to one of the product excipients\n\n         14. History of illicit drug use or alcohol abuse within the previous year\n\n         15. Unresolved meningococcal disease\n\n         16. Pregnancy or lactation\n\n         17. Current cancer or a history of cancer within the 5 years prior to screening with the\n             exception of patients who have successfully treated non-metastatic basal or squamous\n             cell carcinoma of the skin; carcinoma in situ of the cervix; or breast carcinoma in\n             situ\n\n         18. Any medical condition that, in the opinion of the Investigator, might interfere with\n             the patient's participation in the study, poses an added risk for the patient, or\n             confounds the assessment of the patient Active infection with Hepatitis B (HBV),\n             Hepatitis C (HCV) or human immunodeficiency virus (HIV)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895127", 
            "org_study_id": "2013P001292"
        }, 
        "intervention": [
            {
                "arm_group_label": "Soliris (eculizumab)", 
                "intervention_name": "Eculizumab", 
                "intervention_type": "Drug", 
                "other_name": "Soliris"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "intervention_name": "Immunoglobulin", 
                "intervention_type": "Biological", 
                "other_name": "IVIg"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "intervention_name": "Plasmapheresis", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Kidney Transplant", 
            "Renal Transplant", 
            "Rejection", 
            "Antibody mediated", 
            "Humoral", 
            "Eculizumab"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "location": [
            {
                "contact": {
                    "email": "Flavio.Vincenti@ucsfmedctr.org", 
                    "last_name": "Flavio Vincenti, MD", 
                    "phone": "415-353-1322"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94122"
                    }, 
                    "name": "UCSF Medical Center"
                }, 
                "investigator": {
                    "last_name": "Flavio Vincenti, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham and Women's Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Leonardo V Riella, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Reza Abdi, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jamil Azzi, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Edgar Milford, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Steven Gabardi, PharmD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Andrew Siedlecki, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Martina McGrath, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jae Hyung Chang, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "msamanie@med.umich.edu", 
                    "last_name": "Milagros Samaniego", 
                    "phone": "415-353-1322"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan Medical Center"
                }, 
                "investigator": {
                    "last_name": "Milagros Samaniego, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation.", 
        "overall_contact": {
            "email": "achandraker@partners.org", 
            "last_name": "Anil K Chandraker, MD", 
            "phone": "617-732-7412"
        }, 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital", 
            "last_name": "Anil K Chandraker, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary efficacy measure will be the percent change in estimated glomerular filtration rate at 3 months post-treatment using the modified CKD-EPI GFR equation.", 
            "measure": "Change in eGFR", 
            "safety_issue": "No", 
            "time_frame": "Month 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895127"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "Anil K. Chandraker, MD", 
            "investigator_title": "Medical Director of Kidney and Pancreas Transplantation", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Alexion Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}